Abstract:Human breast cancers (BCs) are well recognized for the diagnostic and treatment challenges posed by their extensive and continuously evolving genetic and biologic heterogeneity. Although much progress has been made in identifying features that may serve as new targets, most of these have not been found to be usefully applied to metastatic BCs characterized by a lack of cellular expression of ER, PR, HER2 and a high proliferative activity. Accordingly, these generally incurable BCs, thus identified as "triple-negative" (TNBCs) are in particular need of strategies to model their development in ways that could facilitate the design and testing of effective treatments. Given the drawbacks historically encountered in using cell lines, mouse models, and patient-derived xenografts for this purpose, we launched experiments to assess the potential of creating a useful human model of TNBC de novo. We first discovered that forced expression of KRASG12D (K) alone is sufficient to produce low grade, but persistent human tumors in transplanted immunodeficient NRG mice from 2 of the 3 cell types that constitute and maintain the normal adult human female mammary gland. Histologically, these YB-1-dependent K–induced tumors were classified as variably human ER-, PR- and HER2-positive, invasive ductal carcinomas, also able to produce derivative small tumors in secondary hosts. Subsequent experiments to test whether the indolent properties of these tumors can be modified (i.e., by additional forced expression of human hepatocyte growth factor, or maintenance of transplanted mice on an obesity-inducing diet) showed that neither of these treatments enhance the growth of the K-induced tumors. However, in sharp contrast, transplantation of female NRG mice with the same types of freshly isolated normal adult female mammary cells transduced with lentivirally-encoded BMI1, MYC and TP53R273C and K (KBMT) produced growths containing an increased frequency of Ki67+ cells within a week, and subsequently, produced still YB-1-elevated, but continuously expanding TNBCs. Interestingly, K was required in addition to all 3 of these oncogenes to obtain aggressively expanding TNBCs and, when any one of the BMI1, MYC, or TP53R273C oncogenes was omitted, variably diminished outputs were obtained. FACS analyses showed the surface marker phenotypes of the cells present in any of the more rapidly growing tumors to be remarkably homogeneous with features of normal basal cells. In addition, despite any gross evidence of metastatic capability, cells isolated from all KBMT-induced tumors tested could be expanded in vitro and generated fast growing tumors in transplanted secondary mice. Taken together, these findings demonstrate the feasibility of rapidly and reproducibly creating a model of human TNBC de novo from initially normal human mammary cells, thus offering a new and powerful platform for potentially developing novel prevention, diagnostic, as well as treatment approaches applicable to this disease. Citation Format: Susanna Tan, Davide Pellacani, Sylvain Lefort, Amal El-Naggar, Shengsen Ding, Poul H Sorensen, Martin Hirst, Connie Eaves. Creation and preliminary analyses of a full spectrum of breast cancers initiated de novo from normal human mammary cells [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Breast Cancer Research; 2023 Oct 19-22; San Diego, California. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_1) nr IA16.

Abstract 3267: Human population based engineered breast tumor model for in vivo biomarker discovery

Abstract 320: Perfused 3D Tri-Culture Breast Cancer Microtumors for Accurate Prediction of Drug Response

Abstract B18: Variation in Response to VEGFR Inhibitor Tivozanib in a Unique Population-Based Tumor Model Enables the Development of a Multigene Response Biomarker

Abstract IA16: Creation and preliminary analyses of a full spectrum of breast cancers initiated de novo from normal human mammary cells

Abstract 3906: Ex vivo breast tumors for understanding the patient specific tumor microenvironment remodeling and drug responses

Abstract 4261: Novel Tumor Microenvironment (TME) Restored 3D Cell Culture Model and Humanized Patient-Derived Xenograft Model for Cancer Research and Drug Evaluation

Abstract A062: Somatic engineering of rat models to recapitulate human breast cancer evolution and heterogeneity

Abstract PO5-14-06: Transcriptomics-based drug screening in 3D ex vivo patient-drived breast cancer model and patient biopsy for personalized therapy

Abstract PHB04: Predictive modeling, applied to genetically engineered mouse models of breast or lung cancer, provides insights into major oncogenic pathways

Abstract IA01: Modeling and understanding tumor biologic mechanisms

Abstract LB364: Generation and Application of a Robust Humanized Mouse Tumor Model System for Evaluation of NK-Targeting Therapeutics

Abstract #LB-65: Test of Cytotoxic and Targeted Anticancer Drugs Using Human Primary Non-Small Cell Lung Cancer Xenograft Models

Abstract 2980: An integrated cross-species transcriptional network analysis of metastatic susceptibility

Abstract 86: Deep immuno-profiling of syngeneic tumor mouse models for preclinical studies

Abstract 6429: Critical role of elevated TMEM176B gene expression in humanized patient-derived xenografts mouse models of triple negative breast cancer

Abstract 4600: Phenotypic & functional diversity of tumor associated neutrophils in murine breast tumor models

Single‐cell transcriptional atlas of human breast cancers and model systems

Abstract LB362: Systematic development and characterization of orthotopic animal tumor models: A proactive approach to mimic patients' tumor microenvironments for drug discovery

Abstract 1661: Humanized Mouse Models for Immune-Oncology Biotherapeutics: Development, Validation and Applications

Abstract 2833: Validating cancer biomarker expression on mouse cell-derived xenograft models of human cancer

Abstract B005: Exploring breast cancer heterogeneity in the context of metastatic tumour microenvironments and therapy resistance